Company Profile
Chengdu Acer Biosciences Co., Ltd. (Acer Bio) is a premier preclinical contract research organization (CRO) dedicated to de-risking drug development. Founded by Professor Li Wang, a renowned domestic preclinical efficacy expert who successfully established and operated a top-tier global preclinical CRO, and led by Chairman Cho Man, a veteran entrepreneur with a proven track record in managing Fortune 500 pharmaceutical groups.
We address the critical industry bottleneck where insufficient efficacy accounts for approximately 60% of clinical trial failures. By integrating essential upstream and downstream technologies, resources, and talent, we have built an international, large-scale, and standardized third-party preclinical efficacy evaluation platform. Our mission is to accelerate the translation of innovative therapeutics by providing comprehensive services including druggability assessment(ADMET), advanced formulation optimization, efficacy evaluation, bioanalysis(PK), skilled talent training, and a drug transaction center. We empower partners to reduce R&D risks, make informed investment decisions, and accelerate market entry, striving to become the industry benchmark in efficacy evaluation.
Our platform is designed to support the evaluation of up to 1,000 new drug candidates per year once fully operational. Phase I of our facility—with three core platforms: Pharmacokinetics & Bioanalysis, In Vitro Research, and the Laboratory Animal Center is already in service in June 2023.
So far, we have provided evaluation services to over 200 clients, supporting numerous projects in their clinical applications across global markets, spanning innovative chemical drugs, biologics (nucleic acids, peptides, vaccines), and innovative traditional Chinese medicines.